# OnCo record nct04655092 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04655092/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04655092", "NCT04655092" ;
  schema:name "Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients"@en ;
  schema:description "A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia Japan K.K., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04655092/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04655092> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-01-19" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/essential-thrombocythaemia/>, <https://onco.cc/cancers/polycythaemia-vera/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ropeginterferon-alfa-2b/> ;
  onco:companies <https://onco.cc/companies/pharmaessentia/> .